Tesamorelin is a synthetic growth hormone-releasing hormone peptide derived from the 44-amino-acid sequence of human growth hormone-releasing hormone, also called GHRH or GRF. A hexenoyl modification at the N-terminal tyrosine improves resistance to enzymatic degradation while preserving activity at the human GHRH receptor.
Researchers study tesamorelin because it activates the endogenous growth hormone axis rather than acting as recombinant growth hormone itself. Consequently, the peptide provides a useful model for investigating GHRH receptor signaling, pulsatile growth hormone release, IGF-1 biology, adipose tissue distribution, hepatic metabolism, inflammatory pathways, muscle composition, and selected neurobiological questions.
Tesamorelin also differs from many experimental research peptides because an FDA-approved prescription formulation exists. Therefore, laboratory research material and approved tesamorelin pharmaceutical products must remain clearly distinguished.
Tesamorelin is a synthetic analog of human growth hormone-releasing factor, or GRF(1-44).
According to current FDA labeling, its peptide component contains the same 44-amino-acid sequence as human GRF. However, a trans-3-hexenoyl group attaches to the N-terminal tyrosine. This modification increases resistance to dipeptidyl peptidase-IV-mediated degradation while retaining receptor activity.
The current EGRIFTA WR formulation contains tesamorelin as an acetate salt. The FDA lists a free-base-equivalent molecular weight of 5135.9 Da.
Importantly, the molecular formula shown above describes the FDA-characterized tesamorelin acetate material. Counter-ion composition and water content can affect the measured mass of other preparations.
The 44-residue peptide sequence shown in the FDA structural formula is:
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
A hexenoyl group attaches to the N-terminal Tyr residue.
This structure makes tesamorelin a close analog of endogenous human GHRH rather than a truncated secretagogue or nonpeptide growth-hormone secretagogue.
Tesamorelin has a linear peptide backbone and no cysteine residues. Therefore, disulfide bonds do not determine its tertiary structure.
Its most important engineered feature sits at the N-terminus.
Native GHRH undergoes rapid enzymatic degradation. In contrast, the N-terminal hexenoyl modification helps stabilize tesamorelin while preserving receptor recognition.
The peptide does not use an established metal-binding mechanism. Instead, activity depends primarily on its interaction with GHRHR.
Like endogenous GHRH, tesamorelin engages a class B G-protein-coupled receptor. Receptor activation then influences intracellular cAMP signaling within pituitary somatotroph cells.
Tesamorelin developed from attempts to preserve the biological activity of endogenous GHRH while extending its useful exposure.
Several milestones shaped modern tesamorelin research:
The FDA currently indicates EGRIFTA WR for reducing excess abdominal fat in adults with HIV and lipodystrophy. It explicitly states that the product is not indicated for weight-loss management.
Tesamorelin acts primarily through the GHRH receptor, or GHRHR.
The FDA reports that tesamorelin binds and stimulates human GRF receptors in vitro with potency similar to endogenous GRF.
GHRHR belongs to the class B family of GPCRs.
Pituitary somatotroph cells express this receptor. Once tesamorelin binds, receptor activation stimulates endogenous GH synthesis and secretion.
Therefore, tesamorelin differs mechanistically from direct GH administration.
It stimulates the physiological GH axis upstream.
The major established pathway can be summarized as:
Tesamorelin → GHRHR → Gαs → adenylyl cyclase → cAMP → PKA-associated signaling → GH synthesis and secretion
Growth hormone then interacts with GH receptors in peripheral tissues.
Important target tissues include:
Additionally, GH stimulates production of insulin-like growth factor 1, especially in the liver.
The resulting system becomes:
GHRHR → GH → GHR → IGF-1 / downstream metabolic signaling
The FDA confirms that tesamorelin increases both IGF-1 and IGFBP-3.
Tesamorelin does not simply create one continuous downstream response.
GH secretion remains subject to pituitary and hypothalamic regulation. Therefore, GHRH analog signaling retains more physiological feedback than direct administration of exogenous GH.
Relevant biological responses can include:
However, researchers should distinguish direct tesamorelin/GHRHR effects from downstream GH- and IGF-1-mediated responses.
The GH–IGF-1 axis represents the most firmly established molecular effect of tesamorelin.
Current FDA labeling states that tesamorelin stimulates GH secretion and subsequently increases IGF-1 and IGFBP-3. In Phase 3 studies, researchers did not observe clinically significant changes in TSH, LH, ACTH, or prolactin.
This selectivity makes tesamorelin useful for studying the somatotropic axis.
However, increased IGF-1 also represents an important safety variable.
Among participants receiving tesamorelin for 26 weeks in the clinical development program:
After 52 weeks:
The long-term consequences of persistent IGF-1 elevation remain uncertain.
Visceral adipose tissue, or VAT, has generated the largest clinical evidence base for tesamorelin.
In a 2007 randomized trial involving 412 people with HIV-associated abdominal fat accumulation, participants received tesamorelin or placebo for 26 weeks.
VAT changed by:
Meanwhile, triglyceride concentrations changed by approximately:
The total cholesterol-to-HDL ratio also improved relative to placebo.
A separate 12-month study reported a VAT reduction of approximately 18% among participants who continued treatment.
Importantly, VAT began to accumulate again after tesamorelin discontinuation. This finding suggests that the underlying biological response depends on continued stimulation of the GH axis rather than permanent adipose remodeling.
Tesamorelin has also attracted interest as a research model for hepatic lipid biology.
A 2014 randomized clinical trial included 50 people with HIV and abdominal adiposity.
After six months, tesamorelin produced:
An early increase in fasting glucose appeared at week 2. However, investigators did not find a significant between-group fasting-glucose difference at six months.
A later randomized study examined 61 participants with HIV and hepatic fat fractions of at least 5%.
Participants received tesamorelin or placebo for 12 months.
The estimated treatment effect on hepatic fat fraction was:
−4.1 percentage points
This corresponded to an approximately:
−37% relative reduction
Furthermore, 35% of tesamorelin-treated participants reached hepatic fat fractions below 5%, compared with 4% under placebo.
These findings apply to the studied HIV-associated NAFLD population. They should not automatically be generalized to other hepatic disorders.
Tesamorelin research offers unusually useful human liver transcriptomic data.
Fourman and colleagues analyzed paired liver biopsies from participants in the randomized HIV-associated NAFLD study.
Gene-set enrichment analysis identified changes in several biological pathways.
Tesamorelin increased expression of gene sets linked to:
Researchers observed lower expression of gene sets related to:
Overall, two major gene sets were increased, while 15 gene sets involving inflammatory, proliferative, and tissue-repair biology were reduced at FDR q<0.05.
Importantly, these findings came from liver tissue in a specific HIV-associated NAFLD population.
They do not establish a universal tesamorelin transcriptional signature across every tissue.
A subsequent targeted analysis found changes in several circulating proteins.
Compared with placebo, tesamorelin reduced:
Reported log2 fold changes included approximately:
The same research program also reported reductions in several immune-related proteins, including CCL3, CCL4, CCL13, IL-8, IL-10, CSF1, CD8A, GZMA, and others.
These results suggest interaction between GH-axis augmentation, liver metabolism, and immune biology. However, they do not prove direct GHRHR signaling in each affected cell population.
Tesamorelin has also been studied in skeletal muscle imaging.
An exploratory analysis compared tesamorelin responders with placebo-treated participants.
CT-based analysis showed increased density across several trunk muscle groups.
Treatment-associated differences ranged from approximately 1.56 to 4.86 Hounsfield units.
Researchers also reported increases in lean muscle area and small increases in rectus and psoas cross-sectional area.
However, this was a secondary exploratory analysis. Researchers selected tesamorelin responders based on visceral-fat reduction.
Therefore, these results should generate hypotheses rather than establish a general anabolic effect.
GHRH, GH, and IGF-1 participate in neural biology. Therefore, researchers have also explored tesamorelin outside metabolic research.
A 2012 randomized study enrolled 152 adults aged 55–87, including 66 participants with mild cognitive impairment.
Participants received tesamorelin 1 mg/day or placebo for 20 weeks.
The study reported:
However, the study did not establish tesamorelin as a treatment for cognitive impairment.
A 30-person magnetic resonance spectroscopy substudy reported:
These findings remain preliminary.
Newer studies have produced less definitive results.
A 2025 study in people with HIV, abdominal obesity, and neurocognitive impairment found no significant between-group improvement in overall neurocognitive performance.
Likewise, a 2026 pilot study involving 22 participants found no significant direct treatment effect on the primary study measures after ten weeks of low-dose tesamorelin. Exploratory machine-learning analyses identified possible neuroimaging signals, but these require confirmation.
Therefore, cognitive research should be described as exploratory and mixed, not established.
| Research Area | Model / Study | Duration | Key Quantitative Finding |
|---|---|---|---|
| Visceral adipose tissue | 412 adults with HIV | 26 weeks | VAT −15.2% vs +5.0% with placebo |
| Long-term VAT | Phase 3 extension | 52 weeks | Approximately −18% among continuing participants |
| Liver fat | 50-person randomized study | 6 months | Net liver-fat treatment effect approximately −2.9 percentage points |
| HIV-associated NAFLD | 61-person randomized trial | 12 months | Hepatic fat treatment effect −4.1 percentage points |
| Hepatic transcriptomics | Paired liver biopsies | 12 months | Oxidative phosphorylation increased; 15 inflammation/repair/proliferation gene sets decreased |
| Muscle composition | Exploratory CT analysis | 26 weeks | Muscle-density differences approximately +1.56 to +4.86 HU |
| Cognitive research | 152 older adults | 20 weeks | Executive-function signal and 117% increase in IGF-1 reported |
The FDA states that tesamorelin binds and stimulates human GRF receptors with potency similar to endogenous GRF.
However, publicly accessible regulatory and clinical literature does not establish one standardized nM concentration for all tesamorelin laboratory experiments.
Therefore, researchers should determine concentration according to:
Where possible, laboratories should perform full concentration-response experiments rather than selecting one arbitrary concentration.
Preclinical safety studies used animal models, but animal exposure should remain in the original experimental context.
For example, FDA labeling reports fertility studies in rats using tesamorelin acetate doses up to 0.6 mg/kg.
This was a toxicology/fertility experiment. It should not be converted into a human dosing recommendation.
Historical clinical studies frequently used 2 mg once daily.
However, this should not be confused with an in vitro concentration.
Furthermore, current EGRIFTA WR labeling uses a different pharmaceutical formulation. The FDA states that 1.28 mg of EGRIFTA WR provides systemic exposure comparable with the older 2 mg formulation.
Thus, terms such as tesamorelin 10mg or another vial quantity describe total material quantity only. They do not establish assay concentration, purity, biological activity, or clinical equivalence.
Tesamorelin demonstrates rapid systemic disappearance despite longer downstream endocrine effects.
For current EGRIFTA WR, FDA pharmacokinetic data report:
No formal human metabolism study has established a complete metabolic pathway.
The short plasma half-life does not mean GH and IGF-1 responses disappear in 11 minutes.
Receptor activation initiates downstream endocrine signaling that persists beyond measurable peptide exposure.
Current FDA labeling summarizes clinical safety data from 740 people with HIV-associated lipodystrophy, including 543 participants treated during placebo-controlled phases.
Frequently reported adverse reactions included:
Injection-site reactions occurred in approximately 17% of tesamorelin-treated participants versus 6% with placebo.
GH signaling can influence glucose metabolism.
In FDA-reviewed studies, 5% of tesamorelin-treated participants met an HbA1c threshold for diabetes compared with 1% receiving placebo. The reported hazard ratio was 3.3, with a confidence interval of 1.4–9.6.
Therefore, describing tesamorelin as metabolically “risk-free” would be inaccurate.
Tesamorelin increases endogenous GH and IGF-1.
Consequently, FDA labeling includes precautions concerning:
Long-term cardiovascular safety has not been established for the approved indication.
Tesamorelin can support investigations of:
Researchers can study:
Relevant areas include:
Published human liver research supports work involving:
Tesamorelin provides a useful example of how receptor-level GHRH biology can translate into measurable endocrine and tissue-level effects.
However, translational observations should remain separated from unapproved clinical claims.
Tesamorelin’s 44-residue structure and N-terminal modification create analytical challenges that simple purity percentages cannot fully address.
HPLC can quantify chromatographically detectable components.
A research supplier may specify:
≥98% HPLC purity
However, that number represents a batch or supplier specification.
It is not an inherent property of tesamorelin.
Furthermore:
98% HPLC area ≠ 98% confirmed peptide content.
A stronger analytical package can include:
Analytical methods should confirm both the peptide backbone and modified molecular structure.
Useful research documentation includes:
Depending on experimental use, researchers may consider:
Not every test applies to every experiment.
Testing requirements should follow the intended laboratory model.
Tesamorelin storage requires a clear distinction between FDA-approved pharmaceutical formulations and independent research materials.
Current FDA labeling instructs storage of the unopened EGRIFTA WR 11.6 mg vial at:
20°C to 25°C (68°F to 77°F)
The product should remain in its original box and protected from light. Excursions between 15°C and 30°C are permitted under specified controlled-room-temperature conditions. It should not be frozen.
After reconstitution, the validated WR formulation remains at 20°C to 25°C and unused solution is discarded seven days after mixing.
These FDA conditions apply to the specific EGRIFTA WR formulation.
They should not automatically be copied to unrelated research-grade tesamorelin.
Research stability can depend on:
Therefore:
Storage recommendations may vary by formulation and supplier specification.
Solution-phase peptides can face:
Laboratories should use validated batch-specific stability information whenever possible.
Repeated freeze-thaw cycling should also be minimized unless supporting stability data demonstrate acceptable performance.
Researchers still need to separate systemic GH/IGF-1 effects from tissue-specific responses.
This is particularly relevant to:
The existing human biopsy data make liver biology especially promising.
Future studies can investigate:
Potential biomarkers include:
Researchers should validate predictive biomarkers prospectively before treating them as established response markers.
Current cognitive findings remain inconsistent.
Therefore, future work needs larger cohorts, adequate placebo controls, longer follow-up, imaging endpoints, and well-defined cognitive phenotypes.
The 2025 and 2026 studies reinforce the need for caution rather than confirming a cognitive benefit.
For laboratory work, traceable analytical data matter more than broad marketing terminology.
Where experimental precision requires it, laboratories should independently verify identity and purity.
A useful documentation chain is:
Lot number → HPLC chromatogram → mass spectrum → specification → storage information
This improves reproducibility.
Researchers should monitor possible batch variation involving:
ALLGROWPEPTIDE provides research-focused documentation for qualified peptide materials, subject to batch availability and product specification.
Such a statement should always correspond to documentation actually available for the batch.
Tesamorelin is a 44-residue synthetic GHRH analog that retains the natural human GRF sequence while adding an N-terminal hexenoyl modification. Its primary molecular target is the GHRH receptor. Receptor activation increases endogenous GH secretion, which subsequently raises IGF-1 and IGFBP-3.
Clinical and translational research has produced detailed evidence on visceral adipose tissue, hepatic fat, lipid metabolism, GH/IGF-1 physiology, and safety. In addition, human liver-biopsy studies have revealed changes in oxidative phosphorylation, inflammation, tissue repair, and immune-related pathways.
Other research areas remain less established. Muscle findings come largely from exploratory analyses, while cognitive studies have produced mixed results. Therefore, these fields require further controlled research.
Laboratory interpretation also depends on material quality. HPLC purity alone cannot establish molecular identity, peptide content, or stability. Researchers should consider mass spectrometry, batch-specific documentation, counter-ion status, and appropriate storage data.
Overall, tesamorelin provides a well-characterized model for studying the GHRH–GH–IGF-1 axis and its interactions with adipose, liver, endocrine, and metabolic biology.
Research Use Only: Research-grade tesamorelin materials discussed in the analytical and procurement sections of this page are intended for controlled laboratory research and scientific investigation only. They are not presented as prescription medicines, treatments, diagnostic products, or recommendations for human or veterinary use.
Importantly, tesamorelin is also the active ingredient in FDA-approved prescription EGRIFTA WR for a specific indication in adults with HIV-associated lipodystrophy. Approved pharmaceutical tesamorelin and independently supplied research materials should not be treated as interchangeable or equivalent.
